FDA PULLS CONSTIPATION DRUG
Swiss pharmaceutical maker Novartis AG has
announced that they will stop selling the drug named
ZELNORM out of fear it increases the risk of heart
attack, stroke, or worsening heart chest pain that
can later become a heart attack.
Novartis agreed to withdraw Zelnorm at the FDA's
request, the agency said in a public health
advisory.
Zelnorm, also known as tegaserod maleate, is a
prescription medication which is approved for
short-term treatment of women with irritable bowel
syndrome with constipation and for patients younger
than 65 with chronic constipation.
If you or a loved one have taken Zelnorm and
suffered a heart attack, stroke or other cardiac
related illness
contact the Raphaelson
Law Firm for a fee free comprehensive
consultation. You may be entitled to damages.

